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ABSTRACT
There is growing evidence of the efﬁcacy of treating early staphylococcal infections of prosthetic joints
with surgical debridement and prosthesis retention, combined with oral antibiotic regimens that include
rifampicin in combination with a ﬂuoroquinolone. With rising rates of ﬂuoroquinolone-resistant
staphylococci, evidence concerning the efﬁcacy of alternative combinations of antibiotics is required.
Twenty patients with staphylococcal prosthetic joint infections who had been treated with surgical
debridement and prosthesis retention, and a combination of rifampicin and fusidic acid were analysed.
The mean duration of symptoms before initial debridement was 16 (range 2–75) days. The median time
of follow-up was 32 (range 6–76) months. Treatment failure occurred in two patients. The cumulative
risk of treatment failure after 1 year was 11.76% (95% CI 3.08–39.40%). Two patients had their
treatment changed because of nausea. Ten of 11 patients with infections involving methicillin-resistant
Staphylococcus aureus had successful outcomes. Debridement without prosthesis removal, in combination
with rifampicin and fusidic acid treatment, was effective and should be considered for patients with
early staphylococcal prosthetic joint infections, including those with infections involving ﬂuoroquino-
lone-resistant organisms.
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INTRODUCTION
Prosthetic joint infection is an uncommon but
serious complication of prosthetic joint implanta-
tion, resulting in substantial morbidity, often with
pain, immobility, prolonged hospital stay and
further surgery, and thus additional costs [1,2].
The approach of two-stage exchange arthroplasty
has been preferred for the treatment of prosthetic
joint infections in many centres. This has resulted
in successful outcomes for >80% of patients with
joint replacement infections in various studies [2–
4], but disadvantages include the technical difﬁ-
culty of the surgery involved and the morbidity
and costs of prolonged immobilisation of patients,
who are often elderly [5].
An alternative approach of debridement with
prosthesis retention involves simpler surgery and
potentially minimises the problems associated
with prolonged immobilisation and hospitalisa-
tion. However, cure rates of infection are <40% in
many studies. Where reported, such studies
mostly included cases in which b-lactam-based
antibiotic regimens were used, and a factor that
was associated consistently with a higher risk of
failure was a longer duration of symptoms before
debridement [6–9].
Recent data have demonstrated the efﬁcacy of
treating patients with early (symptoms for
<21 days) staphylococcal orthopaedic implant
infections with retention and debridement of a
stable prosthesis, combined with oral rifampicin
and a ﬂuoroquinolone [10–12]. However, ﬂuoro-
quinolone resistance is now at high levels in
nosocomial strains of staphylococci [13,14], there-
by limiting the usefulness of rifampicin and
ﬂuoroquinolone combinations in this setting.
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These organisms usually remain susceptible to
fusidic acid [14], but there are few data available
to support the use of fusidic acid in combination
with rifampicin for prosthetic joint infections.
Accordingly, the aim of the present study was to
evaluate the efﬁcacy and safety of treating sta-
phylococcal prosthetic joint infections with debri-
dement, prosthesis retention, and the speciﬁc
antibiotic combination of rifampicin and fusidic
acid.
MATERIALS AND METHODS
Study design
A retrospective cohort analysis of a prospectively compiled
register of all patients with prosthetic hip and knee joint
infections at St Vincent’s Hospital, Melbourne, Australia,
between 1998 and 2003 was performed. The clinical manage-
ment of each patient was determined by the responsible
clinicians. Surgical and medical therapies were not standard-
ised for the purpose of the study, although it was common
practice to treat prosthetic joint infections with a short duration
of symptoms with surgical debridement, prosthesis retention
and rifampicin in combinationwith fusidic acid. Prosthetic joint
infections of longer duration (>3 months) were typically treated
with removal of the prosthesis.
Study population
The study population consisted of consecutive patients who
had undergone treatment with one or more surgical debride-
ments with prosthesis retention for a staphylococcal prosthetic
hip or knee joint infection, who then commenced treatment
with rifampicin and fusidic acid. A period of intravenous
antibiotics perioperatively with either a b-lactam or a glyco-
peptide was usual. Patients were excluded from the study if
they had a joint replacement for a previously infected
prosthesis, or if causative organisms other than staphylococci
were isolated.
Deﬁnitions
A staphylococcal prosthetic joint infection was deﬁned by the
isolation of staphylococci from two or more deep culture
specimens, or the isolation of staphylococci from one deep
culture specimen together with either purulence surrounding
the joint at the time of operation, a sinus tract communicating
with the prosthesis, or acute inﬂammation demonstrated on
histopathology of surgical specimens [9]. Treatment failure
was deﬁned as persistence or recurrence of symptoms or signs
of prosthetic infection, the isolation of the same or different
organisms from subsequent surgical samples, or the removal
of the prosthesis while antibiotic therapy continued.
Susceptibility testing
Susceptibility testing of staphylococcal isolates was performed
according to CLSI guidelines for agar and broth dilution. The
MicroScan WalkAway system (Dade Behring Inc., Deerﬁeld,
IL, USA) and agar dilution methods were used for isolates
from 1998 and 1999, and the Vitek-2 system (bioMe´rieux,
Durham, NC, USA) was used for isolates from 2000 until 2003.
Isolates with a fusidic acid MIC £1 mg ⁄L were considered to
be susceptible.
Statistical analysis
The Kaplan–Meier method was used to estimate the 1-year
cumulative risk of treatment failure.
RESULTS
Study population
In total, 29 patients were diagnosed at St Vincent’s
Hospital as having a staphylococcal prosthetic hip
or knee joint infection during the study period.
Five of these patients were excluded from the
study population because they underwent pros-
thesis removal and then either immediate
(two patients) or delayed (three patients) joint
re-implantation as the primary surgical treatment.
Two patients were excluded because there was no
initial surgical intervention. Two other patients
were excluded because they received rifampicin
and ciproﬂoxacin as oral antibiotic therapy. The
medical records did not indicate reasons for the
different surgical or medical treatment approa-
ches taken for each patient.
The remaining 20 patients formed the study
population and met the inclusion criteria of
treatment with surgical debridement, prosthesis
retention, and rifampicin and fusidic acid. Char-
acteristics of individual patients and their out-
comes are summarised in Table 1. The median
age of the study population was 76 years.
Thirteen patients had hip joint replacements
and seven had knee joint replacements. The
indication for the original joint replacement
surgery was osteoarthritis (15 patients), rheuma-
toid arthritis (three patients), aseptic loosening
of a previous prosthesis (one patient), and
reversal of a previous arthrodesis (one patient).
Six patients had type 2 diabetes mellitus, and
four were receiving immunosuppressive medi-
cation.
The median duration from insertion of pros-
thesis until initial debridement (joint age) was 38
(range 12–743) days. The mean duration from onset
of symptoms to initial debridement was 16 (range
2–75) days. No patient showed evidence of pros-
thesis loosening on X-rays or at initial debride-
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ment. No patient had a deﬁnite sinus tract
communicating with the joint.
Microbiology
The organism involved was methicillin-resistant
Staphylococcus aureus (MRSA) in ten patients,
methicillin-susceptible S. aureus (MSSA) in seven
patients, a coagulase-negative staphylococcus
(CNS) that was resistant to methicillin in one
patient, MRSA mixed with MSSA in one patient,
and MSSA mixed with methicillin-susceptible
CNS in one patient. All isolates were susceptible
to rifampicin and fusidic acid. All MRSA isolates
were resistant to ciproﬂoxacin. All MSSA and
CNS isolates were susceptible to ciproﬂoxacin.
Surgical treatment
The mean number of surgical debridements was
2.2 (range 1–4). All debridements were performed
by open arthrotomy, and involved changing
polyethylene liners where possible, removal of
infected soft-tissue, and wash-out of the joint with
high-pressure pulsatile lavage. Typically, the
responsible physicians considered factors such
as duration of symptoms, signiﬁcant purulence of
the joint at initial debridement, ongoing fever or
ongoing wound discharge to assess whether
repeated debridements were required.
Medical treatment
The median duration of intravenous antibiotic
treatment was 12 (range 3–29) days, and the
median duration of hospitalisation for treatment
of the infection was 20 (range 5–81) days. The
median duration of oral antibiotic treatment was
12 (range 6–33) months. Typically, the duration of
treatment was extended if symptom resolution
was initially delayed or if patients were immu-
nosuppressed. Doses administered were exclu-
sively rifampicin 300 mg orally twice-daily and
fusidic acid 500 mg orally three-times-daily.
Patients were informed about the importance of
compliance with the antibiotic regimen, and this
information was reinforced with written patient
information sheets.
Two of the 20 patients reported nausea associ-
ated with rifampicin and fusidic acid treatment
that was sufﬁciently severe to require a change of
treatment. For patient 8, treatment was changed
after 4 days to rifampicin plus ciproﬂoxacin, and
for patient 12, after 2 weeks, to fusidic acid plus
ciproﬂoxacin, both with subsequent improvement
in nausea. These two patients were censored from
the Kaplan–Meier estimation, but continued fol-
low-up (Table 1).
A further two patients experienced transient
nausea, but were able to continue treatment.
Two patients had transient mild rashes and
Table 1. Patient proﬁles and outcomes
Patient
Age (years)/
gender Joint
Joint age
(days)
Symptom
duration (days)
Debridement
procedures Organism
Duration of
intravenous antibiotics
(days)
Duration of
oral antibiotics
(months)
Follow-up
(months)
Treatment
failure
1 75 ⁄Male Hip 22 7 3 MRSA 10 12 29 No
2 76 ⁄ Female Hip 25 17 1 CNS 3 11 24 No
3 63 ⁄Male Knee 21 11 1 MSSA, CNS 5 12 65 Yesa
4 58 ⁄Male Hip 91 75 1 MRSA 6 12 28 No
5 75 ⁄ Female Knee 23 7 2 MSSA 18 12 27 No
6 61 ⁄ Female Hip 57 25 1 MRSA 8 6 31 Yesb
7 63 ⁄Male Hip 743 3 1 MSSAc 10 21 47 No
8 71 ⁄Male Hip 27 8 2 MRSA 29 24d 63 No
9 80 ⁄Male Knee 199 3 2 MSSAc 14 6 6e No
10 80 ⁄ Female Hip 41 22 4 MRSA 12 22 34 No
11 74 ⁄Male Hip 145 6 3 MRSA 18 12 76 No
12 58 ⁄Male Knee 140 8 3 MSSA 21 Ongoingd,f 26 No
13 81 ⁄ Female Knee 34 20 4 MRSA 9 11 28 No
14 83 ⁄Male Hip 75 14 1 MRSA 5 28 50 No
15 74 ⁄ Female Knee 70 62 3 MRSA 19 11 25 No
16 73 ⁄ Female Hip 19 4 4 MSSA 14 17 32 No
17 59 ⁄Male Hip 18 4 1 MSSA 12 24 42 No
18 64 ⁄ Female Hip 17 3 1 MSSA 8 12 48 No
19 72 ⁄ Female Hip 55 9 4 MRSA, MSSA 19 33 70 No
20 74 ⁄ Female Knee 12 2 3 MRSA 14 12 26 No
MRSA, methicillin-resistant Staphylococcus aureus; CNS, coagulase-negative staphylococcus; MSSA, methicillin-susceptible S. aureus.
aProsthesis replaced after 12 months because of instability while still receiving antibiotics. No evidence of infection at further surgery.
bOngoing symptoms of infection with rifampicin-resistant CNS and Enterococcus faecalis isolated at change of prosthesis at 7 months.
cClinical features suggest infection possibly acquired by haematogenous seeding.
dAntibiotic treatment modiﬁed because of nausea.
ePatient died from unrelated cause during treatment.
fTreatment duration extended because of immunosuppression.
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pruritus early in treatment, which improved
without discontinuation of treatment. Two
patients had a perioperative thromboembolic
episode, and one male patient had traumatic
urinary bladder catheterisation during
admission. There were no episodes of hepatox-
icity.
Follow-up
Patients were followed closely as outpatients,
with review initially on a monthly basis. The
median duration of follow-up was 32 (range 6–76)
months from the time of infection. The median
time of follow-up after discontinuing antibiotics
was 16 months.
Outcomes
There was no evidence of treatment failure for 18
patients. Sixteen of these patients retained their
original prosthesis and were followed for
>12 months after discontinuing antibiotics. One
patient (patient 12) had no evidence of infection
after 26 months of follow-up, but the responsible
physicians chose to undertake a course of sup-
pressive antibiotic therapy because of signiﬁcant
immunosuppression. One patient (patient 9) died
6 months after initial debridement from unrelated
causes.
There was evidence of treatment failure in
two patients. In one of these patients (patient 6),
who initially had an infection with MRSA, signs
of infection were ongoing and further surgery
was required 6 months after initial debridement.
Intra-operative cultures yielded different organ-
isms (a rifampicin-resistant CNS and an Entero-
coccus faecalis). In the other patient (patient 3),
there was evidence of prosthetic loosening, with
pain, after treatment for 12 months, and ex-
change arthroplasty was therefore undertaken.
Histology of tissue taken during further surgery
showed a foreign body-type reaction. There was
no other clinical, biochemical or microbiological
evidence of infection, and the patient remained
free of signs of infection after a further
65 months.
The cumulative risk of treatment failure at
1 year was 11.76% (95% CI 3.08–39.40%). Ten of
11 infections involving MRSA, eight of nine
infections involving MSSA, and one of two
infections with CNS were resolved.
DISCUSSION
The approach of debridement with prosthesis
retention, combined with treatment with oral
rifampicin and fusidic acid, was successful in this
study, with only two of 20 patients failing
treatment with this regimen after a median
follow-up period of 32 months. The two patients
who failed treatment did not show evidence of
persistence of the original infecting organisms.
The 1-year cumulative risk of treatment failure of
11.76% compares favourably with those in other
studies examining treatment with debridement,
prosthesis retention, and a combination of rif-
ampicin and ﬂuoroquinolones [10–12], in which
up to 100% of patients who were able to complete
the treatment had a successful outcome. Among a
subgroup of 11 patients in the present study
cohort who had MRSA infections, for whom
ﬂuoroquinolones were not a treatment option
because of primary resistance, ten had a success-
ful outcome. This was notably more successful
than outcomes published previously concerning
treatment of MRSA infections with prosthesis
retention and other antibiotics [11,12].
It is important to note that the results of the
present study cannot be generalised to all pros-
thetic joint infections. Each patient in the study
exhibited several features that have been shown
previously to be associated with good success
rates, namely a short period of time from onset of
symptoms until initial debridement, with a mean
of 16 (range 2–75) days, a stable prosthesis, and
the absence of a deﬁnite sinus tract [6–10]. The
utility of the study treatment regimen in patients
without these good prognostic factors is un-
known.
Rifampicin and fusidic acid have good activity
against most staphylococci, and have retained
activity against the majority of methicillin-resist-
ant and ﬂuoroquinolone-resistant staphylococci
isolated in most parts of the world [14,15]. These
antimicrobial agents are well-absorbed after oral
administration, and demonstrate excellent penet-
ration into tissues and the intracellular space [16].
Rifampicin has demonstrated excellent efﬁcacy
against slow-growing organisms and organisms
associated with bioﬁlms, both of which are
important in the pathogenesis of infections invol-
ving prosthetic material [17–19].
Resistance develops quickly in staphylococcal
infections when either of these antibiotics is used
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alone. However, the risk of emergence of resist-
ance is considerably reduced when the agents are
used in combination [15,16,19]. Patients in the
present study received extensive verbal and
written instructions concerning the importance
of compliance, and were carefully monitored as
outpatients. This close attention to optimising
compliance was probably an important factor in
the good success rate seen in this patient group.
Rifampicin and fusidic acid are generally well-
tolerated, as was the case in this study. Important
known side-effects are nausea, allergic reactions
and abnormalities in liver function test results
[16]. Two patients in this study with MSSA
infections developed nausea that was sufﬁciently
severe to require a change in the antibiotic
regimen. Nausea has been a limiting factor when
these antibiotics have been used previously to
treat orthopaedic implant infections [10,20].
A previous study evaluated the treatment of
patients with staphylococcal orthopaedic implant
infections with retention of the implant and a
combination of rifampicin 900 mg ⁄day with
either fusidic acid 500 mg twice-daily or oﬂoxacin
[20]. Cure rates for prosthetic joint infections were
low (33% for knee prostheses and 41% for hip
prostheses). Infected prostheses did not necessar-
ily undergo early surgical debridement. Rifamp-
icin-resistant staphylococci were responsible for
most of the treatment failures in the fusidic acid
group, resulting in the conclusion that fusidic acid
500 mg three-times-daily may have been more
appropriate to prevent the emergence of rifamp-
icin resistance. There was no signiﬁcant difference
in outcomes between the fusidic acid and oﬂoxa-
cin groups.
In the present study, patients generally under-
went debridement via open arthrotomy, and
debridements were repeated if necessary. Poly-
ethylene liners of prostheses were changed, if
possible, to enable greater access to infected
tissues. There is already evidence that an
approach involving more extensive surgical
debridement results in better outcomes than less
extensive or arthroscopic debridement [4].
Recommendations published recently include
rifampicin in combination with fusidic acid as
an option after debridement and prosthesis
retention for the management of early prosthetic
joint infections [21,22]. This option is particularly
useful in the case of MRSA infections, where
ﬂuoroquinolone resistance is common, or where
the patient shows intolerance to ﬂuoroquinolones.
To our knowledge, the present study is the ﬁrst to
examine the efﬁcacy of this treatment protocol.
Although further controlled and prospective
studies that include functional outcomes and
shorter treatment durations are required, the
present study suggests that debridement without
prosthesis removal, combined with oral rifampi-
cin and fusidic acid, is a good alternative for the
treatment of early staphylococcal prosthetic joint
infections.
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